Robeco Institutional Asset Management
ADPT icon

Robeco Institutional Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Robeco Institutional Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,652
Closed -$162K – 838
2026
Q1 		$162K Hold
11,652
– – ﹤0.01% 838
2025
Q4 		$189K Buy
+11,652
New +$190K ﹤0.01% 819

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Robeco Institutional Asset Management's ADPT Position: Q2 2026 in Review

Robeco Institutional Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 11,652 shares — an estimated $162K sold.

Robeco Institutional Asset Management first reported a position in ADPT in Q4 2025 and held it in 2 quarters. The position peaked at $189K in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Robeco Institutional Asset Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 11,652 Adaptive Biotechnologies shares in Q2 2026, an estimated $162K.
  • Robeco Institutional Asset Management first reported a position in Adaptive Biotechnologies in Q4 2025 and held it in 2 quarters.
  • Robeco Institutional Asset Management's Adaptive Biotechnologies position peaked at $189K in Q4 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.